Itron Q4 Regulatory Approval Delays Drag Shares Down 10.7%
Itron shares fell 10.68% over the past month after slower-than-anticipated regulatory approvals hurt Q4 performance, making the company a major detractor in Aristotle Small Cap Equity Fund’s portfolio. At $89.36 closing price on February 13 and $4.09 billion market cap, Itron is positioned for 2026 grid modernization demand.
1. Q4 Performance Drag
Itron was flagged as a top detractor in a major small-cap equity fund’s Q4 2025 portfolio after regulatory approval processes slowed more than investors expected.
2. Recent Stock Metrics
As of February 13, 2026, Itron closed at $89.36 per share, posting a one-month decline of 10.68% and a 7.88% drop over twelve months, with a market capitalization of $4.093 billion.
3. 2026 Growth Outlook
Management and shareholders anticipate regulatory approvals to pick up in 2026, supporting demand from power grid modernization efforts for Itron’s smart metering and grid monitoring solutions, which underpins the retained fund position.